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Abstract
Introduction: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a
study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine
effectiveness.
Methods: VE against influenza and/or pneumonia was assessed in the cohort study (n.25000), and vaccine effectiveness
against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios
(OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine
effectiveness was estimated as (1-odds ratio)*100%.
Results: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was
98% (84–100%) and 33% (2–54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18–59 years old
subjects, and was 49% (16–69%) effective in 60 years and older subjects.
Conclusions: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has
played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in
preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years
and older subjects.
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Introduction
Approximately six months after the emergence of
A(H1N1)pdm09 influenza in April 2009, new vaccines against
the pandemic A(H1N1)pdm09 virus appeared on the market.
According to the Dutch Health Council advice several risk groups
were recommended to receive the pandemic vaccine (see Table 1).
In the Netherlands, the vaccination campaign against the
influenza A(H1N1)pdm09 started at the beginning of November
2009, when the incidence of A(H1N1)pdm09 influenza reached its
peak [1,2], see Figure 1 [3]. Two doses - at least two weeks apart -
were scheduled, with the influenza A(H1N1)pdm09 vaccination
starting two weeks after the seasonal influenza vaccination.
Studies have shown that A(H1N1)pdm09 pandemic vaccines
were very immunogenic [4,5]. However, clinical effectiveness
estimates of A(H1N1)pdm09 vaccine seem to vary. In a multi-
centre European study the effectiveness of monovalent
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A(H1N1)pdm09 vaccines in preventing laboratory-confirmed
influenza of about 70% was estimated [6]. The non-adjuvanted
A(H1N1)pdm09 influenza vaccine appeared to be more effective
in younger adults and was estimated to prevent 50 to 90% of
laboratory-confirmed influenza [7,8]. More data are available
about MF59- and AS03-adjuvanted vaccines that in Europe were
more commonly used during the pandemic. The AS03-adjuvanted
vaccine prevented up to 95% of laboratory-confirmed influenza in
the general population [9], and was much less effective (VE 41%,
95% CI 271%–80%) in the 50 years old and older risk group
subjects [10]. MF59-adjuvanted vaccine effectiveness in prevent-
ing medically attended influenza-like illness (ILI) in subjects of 60
years and older was 25% [11], and it showed to be quite low
against more specific laboratory-confirmed A(H1N1)pdm09 influ-
enza outcomes as well [2,12].
Because of the substantial variability in published vaccine
effectiveness estimates and limited information on the MF59-
adjuvated A(H1N1)pdm09 pandemic vaccine effectiveness in
preventing different outcomes, we aimed to provide further
evidence about its effectiveness against influenza and/or pneumo-
nia, and laboratory-confirmed A(H1N1)pdm09 influenza. We
achieved this by conducting a cohort and a matched case-control
Figure 1. Number of specimens positive for influenza by subtype in the Netherlands [3]. Different colours mark different influenza
subtypes.
doi:10.1371/journal.pone.0066125.g001
Table 1. Organization of 2009/2010 influenza vaccination campaign in the Netherlands (based on [19,29,30].
Risk groups
Provider of the
vaccinations
A(H1N1)pdm09
vaccine used
Eligible for 2009/2010
seasonal influenza vaccination
Family members and caretakers of individuals with
high risk for severe disease or death, institutionalized
individuals, those suffering from underlying medical
conditions (pulmonary disease, cardiac disease,
diabetes mellitus, chronic kidney failure, cancer,
immunocompromising conditions), and healthy
elderly .= 60 years old
General practice Focetriab Eligible
Children aged 6 months up to and including 4 years
and household members of children younger
than 6 months
Community Health Services Pandemrixa Not eligible
Pregnant women in their second and third trimester General practice Focetriab Not eligible
Health care workers in contact with high risk groups Occupational Health
Physician
Focetriab Eligible
aFocetria is MF59-adjuvanted vaccine produced by Novartis.
bPandemrix is AS03-adjuvanted vaccine produced by GSK.
doi:10.1371/journal.pone.0066125.t001
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study in a population of adults with underlying medical conditions
and (healthy) 60 years and older persons that received MF59-
adjuvanted Focetria vaccine.
Methods
Ethics Statement
Both studies were conducted in accordance with the Dutch Law
for the Protection of Personal Data (Wet Bescherming Persoons-
gegevens) [13] and the Declaration of Helsinki [14]. In the case-
control study, the cases agreed to participate in the study by
signing and returning the informed consent and patient informa-
tion forms. Based on the Dutch Law for the Protection of Personal
Data no medical ethical committee approval was required for
these studies, therefore the medical ethical committee was not
contacted.
The Cohort Study
We conducted a retrospective cohort study in 25743 18 years
and older subjects, who belonged to one of the risk groups that
were recommended to receive influenza vaccinations in 2009, i.e.
adults with underlying medical conditions or 60 years and older
subjects. The anonymous data were received from the Netherlands
Information Network of General Practice (LINH) database, which
includes demographic and clinical information collected from a
representative network of general practices spread throughout the
Netherlands [15]. Individuals in our cohort were vaccinated with
MF59-adjuvanted pandemic influenza vaccine (FocetriaH by
Novartis [16]). A subject was considered as vaccinated if at least
one dose of the vaccine against A(H1N1)pdm09 influenza was
administered. As individual vaccination dates were not available,
and the vaccination campaign took off at the beginning of
November, we assumed that the vaccine would start demonstrat-
ing its effectiveness in the middle of November, i.e. .= 7 days
after receiving the vaccine.
The outcome of the study was influenza and/or pneumonia
coded as R80 and R81 according to the International Classifica-
tion of Primary Care coding system (ICPC) [17]. The main
outcome occurrence period was between November 15 and
December 31, 2009. Subjects with a record of influenza after the
World Health Organization declared the A(H1N1)pdm09 pan-
demic on June 11, 2009 and before the vaccination campaign was
anticipated to have an effect (November 14, 2009) were excluded.
Several demographic and clinical characteristics were included
as covariates. Demographic characteristics recorded were sex and
age. Clinical characteristics included underlying medical condi-
tions, seasonal influenza vaccination status, and a number of visits
to the general practice (GP visits). Underlying medical conditions
were grouped into lung diseases, diabetes mellitus, breathing
problems due to neurological disorders, cardiovascular diseases,
chronic kidney failure, HIV and other immunocompromising
conditions (Appendix S1). Seasonal influenza vaccination was
recorded positively when a single dose of a seasonal influenza
vaccine in 2009 was received. A number of GP visits between
October 1 in 2008 and October 1 in 2009 divided into three
categories (,= 2; 3–13, and .= 14 visits) was obtained as an
indicator for the severity of health problems.
To be able to address the unmeasured confounding as well as
calendar time, influenza and/or pneumonia were recorded during
the reference period, i.e. before the vaccine was anticipated to
demonstrate its effectiveness (June 11– November 14, 2009). Odds
ratio of one indicating no effectiveness of an intervention was
expected, a departure from one indicating the bias.
We used descriptive statistics and univariate logistic regression
to compare the characteristics of vaccinated and unvaccinated
subjects. Odds ratios (OR) and their 95% confidence intervals
(95% CI) derived from the univariate and multivariate logistic
regression were used to estimate the unadjusted and adjusted
A(H1N1)pdm09 influenza vaccine effectiveness (VE) calculated as
(1-OR)*100%. The analysis was also stratified by age into the
groups of 18–59 and .= 60 years old. To adjust for unmeasured
confounding, we used a method proposed by Weiner et al. [18],
where the odds ratio when the vaccine was expected to
demonstrate an effect was divided by the odds ratio when the
vaccine was expected not to demonstrate any effect. Confidence
intervals were obtained by bootstrapping the original sample for
1000 times and calculating the unmeasured confounding adjusted
estimates for each sample. The estimates were sorted, and the
2.5% and 97.5% quintiles indicated the lower and the upper limit
of the 95% CI.
The Matched Case-control Study
The data about the A(H1N1)pdm09 positive cases came from
four Community Health Services (CHSs) who were registering
laboratory-confirmed A(H1N1)pdm09 influenza cases in four
provinces in the Netherlands. The patients presenting with the
influenza-like illness symptoms to the GP throughout the
pandemic where swabbed independent of the influenza vaccina-
tion status and when positive for A(H1N1)pdm09, reported to the
CHS covering the region. The cases were matched with the
controls from a previously described cohort in a ratio of 1:10 on
sex, age (number of years) and underlying medical conditions
(none versus one or more).
A control subject was considered as vaccinated if at least one
dose of the vaccine against A(H1N1)pdm09 influenza was
recorded in the LINH database. A case was considered as
vaccinated if at least one dose of A(H1N1)pdm09 vaccine was
administered .= 7 days before a subject was registered with a
laboratory-confirmed A(H1N1)pdm09 influenza at one of the
CHSs. The main source of information of the cases was the GP
files; self-reported vaccination status was used if vaccination status
was not recorded in the GP files. When vaccination dates were
unknown, vaccine effectiveness was calculated under the assump-
tion that these subjects were not vaccinated and under the
assumption that these subjects were vaccinated.
The main study outcome was notification with laboratory-
confirmed influenza A(H1N1)pdm09 between 12 November and
31 December in 2009 (Appendix S2). The sample of controls
consisted of subjects from the LINH database who were not
registered with influenza during the A(H1N1)pdm09 influenza
season from 11 June to 31 December in 2009.
Demographic characteristics for the cases were obtained
through a questionnaire. Information about the underlying
medical conditions (Appendix S3) prior to 1 October 2009 was
collected from the GP files. Information about the demographic
characteristics and underlying medical conditions for the controls
was obtained from the LINH database.
Vaccine effectiveness (VE) was calculated by using OR and
their 95% CI derived from the conditional logistic regression:
VE = (1-OR)*100%.
Results
The Cohort Study
In total, the cohort consisted of 25743 individuals who were
recommended to receive influenza vaccinations in 2009. The
number of subjects included in the vaccine effectiveness analysis
A(H1N1)pdm09 Influenza Vaccine Effectiveness
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during the period when vaccine was anticipated to demonstrate
the effect was 25568, as 175 subjects were registered with influenza
before the A(H1N1)pdm09 vaccination campaign was anticipated
to have an effect.
Seventy-three percent of the study population received at least
one dose and 66% received two doses of A(H1N1)pdm09
influenza vaccine. Vaccinated individuals were slightly older and
had more underlying medical conditions (Table 2). With respect to
demographic characteristics, A(H1N1)pdm09 and seasonal influ-
enza vaccination status, and underlying medical conditions our
sample was similar to the LINH sample [19].
After adjustment for demographic and clinical characteristics,
the odds ratios in the total sample decreased from 0.83 to 0.67,
resulting in the vaccine effectiveness estimate of 33% (Table 3).
The vaccine effectiveness dropped to 25% after adjusting for
unmeasured confounding (0.83/1.10), although it became not
statistically significant (0.75, 95% CI 0.47–1.17).
When we stratified the analysis by age, the vaccine remained
effective only in 60 years old and older subjects, and there seemed
to be no unmeasured confounding (OR of 1 during the reference
period).
The Matched Case-control Study
Of the 119 approached individuals who were notified by the 4
GGDs with A(H1N1)pm09 influenza between 12 November and
31 December in 2009, 29 subjects (24%) decided to join the study.
Sixteen subjects were eligible to be included in the final analysis
because they belonged to one of the risk groups that were
recommended to receive annual influenza vaccinations, i.e. had at
least one underlying medical condition or were healthy 60 years or
older subjects.
A dataset consisted of 16 case-control pairs matched 1:10. The
majority of cases (11/16) were subjects of 18–59 years old and had
at least one underlying medical condition. Overall, the most
common underlying medical conditions among the cases were
lung and cardiovascular diseases, 7 and 5 respectively.
At least one dose of the A(H1N1)pdm09 influenza vaccine was
received by 75% of the controls, which was similar as in the risk
groups in the LINH cohort [19]. Only one subject (6.3%) received
one dose of the A(H1N1)pdm09 vaccine .= 7 days before being
notified with A(H1N1)pdm09 influenza, and for five cases the
information about the vaccination dates was not available. When
we assumed that the persons with unknown vaccination dates were
vaccinated, vaccine effectiveness was 80% (41–93%), and it
increased to 98% (84–100%) when we assumed that these persons
were not vaccinated (Table 4).
Discussion
Our results indicate that immunization with MF59-adjuvanted
vaccine was preventive against laboratory-confirmed
A(H1N1)pdm09 influenza. Furthermore, vaccine effectiveness
against influenza and/or pneumonia increased after adjusting for
measured confounding, although the estimate was not statistically
significant after adjusting for unmeasured confounding. The
results of the cohort study have also suggested that the vaccine
was only effective in 60 years old and older individuals, and in this
group there seemed to be no unmeasured confounding. Higher
vaccine effectiveness in this group might be explained by cross-
protective antibodies due to previous exposure to H1N1 influenza
[20] as subjects born before 1950 and who were probably exposed
to a descendant of the 1918 H1N1 pandemic virus had higher
antibody titres against A(H1N1)pdm09 influenza than younger
individuals [21,22].
Strengths and Limitations
In our study we were able to assess both, more and less specific
outcomes such as laboratory-confirmed influenza and influenza
and/or pneumonia as registered in the GP database. Nevertheless,
some selection bias might have occurred in our outcome measure
since influenza is not clearly distinguishable from other acute
respiratory infections on the basis of its clinical profile, and
therefore influenza cases in our cohort might represent influenza-
like illness rather than influenza. On the other hand, as the main
circulating virus in 2009/2010 season was A(H1N1)pdm09,
patients presenting themselves with influenza-like symptoms were
most likely registered as influenza. Some potential for biases in a
case-control study might have occurred because of different
sources of data on cases and controls as well: only the individuals
that did not have registered visits due to influenza (R80 code
according to ICPC) during the A(H1N1)pdm09 influenza
pandemic between 11 June –31 December, 2009 were included
Table 2. Descriptive characteristics of subjects vaccinated and unvaccinated against A(H1N1)pdm09 influenza (N= 25568).
Vaccinated Unvaccinated OR (95% CI)
N=18774 (73.4%) N=6794 (26.6%)
Male sex 8692 (46.3) 3316 (48.8) 0.90 (0.86–0.96)
Age in years 63.5 (15.1) 57.7 (16.4) 1.02 (1.02–1.03)
Lung diseases 4895 (26.1) 1417 (20.9) 1.34 (1.25–1.43)
Immunocompromised conditions and HIV 976 (5.2) 214 (3.1) 1.69 (1.45–1.96)
Diabetes mellitus 3535 (18.8) 726 (10.7) 1.94 (1.78–2.11)
Cardiovascular disease 9311 (49.6) 2103 (31.0) 2.20 (2.07–2.33)
Kidney insufficiency 312 (1.7) 68 (1.0) 1.67 (1.28–2.18)
Breathing problems due to neurological disorders 195 (1.0) 61 (0.9) 1.16 (0.87–1.55)
GP visits: ,=2 2806 (14.9) 2051 (30.2) Reference
3–13 8983 (47.8) 3449 (50.8) 1.90 (1.78–2.04)
.=14 6985 (37.2) 1294 (19.0) 3.95 (3.63–4.28)
Seasonal influenza vaccination 16642 (88.6) 1781 (26.2) 21.97 (20.48–23.57)
doi:10.1371/journal.pone.0066125.t002
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as controls, while cases were subjects with laboratory-confirmed
A(H1N1)pdm09 influenza throughout the study period. As
virological testing was only done in the general practice for severe
influenza cases, patients with less severe influenza who did not
contact the GP were not captured. Hence, A(H1N1)pdm09
influenza incidence in the cohort, and therefore control population
of a case-control study, might be underestimated and therefore
lead to vaccine effectiveness underestimation.
Although A(H1N1)pdm09 influenza vaccination status was
recorded, the individual vaccination dates of the cohort were not
known. We therefore limited the period when we assessed the
vaccine effectiveness to when we anticipated that the vaccine
would already have had an effect. When the vaccination dates of
cases were not known, we performed the statistical analysis under
two scenarios, when we assumed that the subjects with unknown
vaccination dates were vaccinated, and when we assumed that the
subjects with unknown vaccination dates were not vaccinated.
However, due to a moderate response rate of the cases and
absence of information on vaccination status for non-responders,
we cannot exclude the self-selection bias due to vaccination status
of the responders. Still, since the estimated vaccine effectiveness
was reaching more than 80%, it is unlikely that such selection bias
can explain the findings.
As evidence about influenza vaccine effectiveness usually comes
from observational studies, efforts should be put to control for bias
and confounding. When the nature of the data allows it,
adjustment for measured as well as unmeasured confounding
should therefore be incorporated [23,24]. Although we were not
able to address the unmeasured confounding in our case-control
study, by matching on several baseline characteristics, we
addressed some of the measured confounding. In our cohort
study we adjusted for measured confounding and we controlled for
unmeasured confounding by dividing the vaccine effectiveness
estimates during the period when we anticipated the vaccine to
have an effect by an estimate during a reference period when we
did not anticipate the vaccine to have an effect.
Use of diagnoses of underlying medical conditions based on
ICPC, although might have some coding errors and disease
severity measure is not directly available, is otherwise a valid and
reliable way to measure health in large populations [25,26]. Use of
GP based data also reassures continuity of the data. Besides, only
the records from the GPs that delivered good-quality data to
LINH were made available for this study.
Finally, our results should not be directly extrapolated to the
situation of seasonal influenza because the affected vulnerable
groups during the seasonal and the A(H1N1)pdm09 influenza
seasons appeared to differ. The population severely affected during
the 2009 pandemic was younger as compared to the population
usually affected by the seasonal influenza [27]. As compared to the
seasonal virus H3N2, A(H1N1)pdm09 influenza was also less
severe in terms of significant cause of illness in older adults [28].
Additionally, seasonal and pandemic vaccination statuses were
highly correlated as nearly the same population received both
vaccines. To avoid multicolinearity we therefore did not include
seasonal influenza vaccination status as a covariate in the multiple
logistic regression model. Moreover, as there is not enough
evidence about the cross-protection by the seasonal influenza
vaccine against the A(H1N1)pdm09, we did not assess seasonal
influenza vaccine effectiveness against the A(H1N1)pdm09 influ-
enza.
Table 3. A(H1N1)pdm09 influenza vaccine effectiveness to prevent influenza and/or pneumonia: a cohort study between 11 June
–31 December 2009.
Study period (November 15– December 31, 2009) Reference period (June 11– November 14, 2009)
Exposed Unexposed OR (95% CI)* OR (95% CI)** OR (95% CI)*
Total sample 18774 6794
Influenza and/or pneumonia 96 42 0.83 (0.57–1.19) 0.67 (0.46–0.98) 1.10 (0.86–1.41)
Subjects .= 60 years old 13410 3967
Influenza and/or pneumonia 52 24 0.64 (0.39–1.04) 0.51 (0.31–0.84) 1.00 (0.71–1.41)
Subjects 18–59 years old 5364 2827
Influenza and/or pneumonia 44 18 1.29 (0.74–2.24 1.07 (0.61–1.88 1.41 (0.98–2.02
OR – odds ratio; 95% CI –95% confidence interval.
*Unadjusted.
**Adjusted for sex, age, underlying medical conditions and GP visits (stratified by age analysis adjusted only for GP visits).
doi:10.1371/journal.pone.0066125.t003
Table 4. A(H1N1)pdm09 influenza vaccine effectiveness to prevent laboratory confirmed A(H1N1)pdm09 influenza: a matched
case-control study between 12 November –31 December 2009.
Vaccinated cases/cases Vaccinated controls/controls Crude odds ratio (95% CI) Vaccine effectiveness (95% CI)
1/16 120/160 0.02 (0.003–0.18)* 98% (82–100%)*
6/16 120/160 0.20 (0.07–0.59)** 80% (41–93%)**
*Crude odds ratio, its 95% confidence interval and the corresponding vaccine effectiveness estimates for the assumption that persons whose vaccination status was
missing or unavailable were not vaccinated;
**Crude odds ratio, its 95% confidence interval and the corresponding vaccine effectiveness estimates for the assumption that persons whose vaccination status was
missing or unavailable were vaccinated.
doi:10.1371/journal.pone.0066125.t004
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Conclusion
The vaccine against A(H1N1)pdm09 influenza appeared to be
effective against laboratory-confirmed influenza. The vaccine was
also effective against influenza and/or pneumonia, notably in
subjects of 60 years and older. It is difficult to estimate what (if any)
part of the effectiveness of the vaccine in 60 years and older
subjects might be explained by previous cross-protection.
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